Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

0.6300 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64
Open 0.6300
Bid (Size) 0.6401 (1)
Ask (Size) 0.6500 (5)
Prev. Close 0.6300
Today's Range 0.6300 - 0.6300
52wk Range 0.5010 - 1.350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Autoimmunity Patients Face Cost, Diagnosis, Care Challenges
Via Investor Brand Network
New, Deadly Infectious Diseases Could Emerge as Climate Change Worsens
Via Investor Brand Network
Topics Climate Change
Exposures Climate

Performance

YTD
-51.54%
-51.54%
1 Month
-1.10%
-1.10%
3 Month
-51.54%
-51.54%
6 Month
-51.54%
-51.54%
1 Year
-51.54%
-51.54%

More News

Read More
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit
Via Investor Brand Network
Topics Economy
Exposures Economy
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance
Via Investor Brand Network
Potential Complications of Untreated Psoriasis
Via Investor Brand Network
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB
Via Investor Brand Network
Exposures COVID-19
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Study Identifies Immune Cells Responsible for Severe Asthma
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023
Via Investor Brand Network
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event
Via Investor Brand Network
Five Ways to Treat Infectious Diseases While Keeping Antimicrobial Resistance in Check
Via Investor Brand Network
Exposures COVID-19
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients
Via Investor Brand Network
Researchers ID Biomarker That Could Improve Autoimmune Disease Treatment
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Syndromic Testing Could Transform Infectious Disease Diagnosis
Via Investor Brand Network
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Researchers Find Psoriasis Increases Risk of Heart Disease
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at CPHI Barcelona 2023, Other Upcoming Events
Via Investor Brand Network
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development
Via Investor Brand Network
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.